Paul Larsmon has worked as a broadcast television journalist for 25 years, covering general news, business and politics. He has been both presenter and producer in several news broadcasters, including the major British television news company ITN. He joined PharmaTelevision as Executive Producer earlier this year and has been responsible for getting , PTV News launched.
Harren Jhoti
President and Director
Harren Jhoti presently serves as President and Director of Astex Pharmaceuticals. Harren Jhoti PhD, has served as Astex Pharmaceuticals president and member of the Board of Directors since July 2011. He co-founded Astex Therapeutics in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. Dr. Jhoti was named by the Royal Society of Chemistry as "Chemistry World Entrepreneur of the Year"for 2007. He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti served as a non-executive director of Iconix Inc. Before starting up Astex Therapeutics in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a BSc (Hons) in Biochemistry in 1985 and a PhD in Protein Crystallography from the University of London in 1989.
James S.J Manuso
Chairman and CEO
James Manuso PhD, MBA, currently serves as chairman and chief executive officer at Astex Pharmaceuticals. He served as Astex Pharmaceuticals (formerly SuperGen) chairman, president and CEO from January 2004 to July 2011, as chief executive officer-elect from September 2003 to December 2003 and as a director since February 2001. He is co-founder and immediate past president and chief executive officer of Galenica Pharmaceuticals, Inc. Dr. Manuso co-founded and was general partner of PrimeTech Partners, a biotechnology venture management partnership, from 1998 to 2002, and co-founder and managing general partner of The Channel Group LLC, an international life sciences corporate advisory firm. He was also president of Manuso, Alexander & Associates, Inc, management consultants and financial advisors to pharmaceutical and biotechnology companies. Dr. Manuso was a vice president and director of Health Care Planning and Development for The Equitable Companies (now Group Axa), where he also served as an acting medical director. He currently serves on the boards of Novelos Therapeutics Inc. (NVLT:OB) and privately held KineMed, Inc. Previously, he served on the boards of Merrion Pharmaceuticals Ltd (MERR:IEX; Dublin, Ireland), Inflazyme Pharmaceuticals Inc., Symbiontics Inc. (subsequently sold to BioMarin as ZyStor Therapeutics Inc.), Quark Pharmaceuticals, Inc., Galenica Pharmaceuticals Inc, and Supratek Pharma Inc Dr. Manuso earned a BA with Honors in Economics and Chemistry from New York University, a PhD in Experimental Psychophysiology from the Graduate Faculty of The New School University, a Certificate in Health Systems Management from ,Harvard Business School and an Executive MBA from Columbia Business School. Dr. Manuso is the author of over 30 chapters, articles and books on topics including health care cost containment and biotechnology company management. He has taught and lectured at Columbia, New York University, Georgetown, Polytechnic University, Waseda University (Japan) and elsewhere. He has delivered invited addresses at meetings of the American Management Association, the American Medical Association, the Securities Industry Association, the Biotechnology Industry Organization and many other professional associations. Dr. Manuso serves on the Board of Directors of the Biotechnology Industry Organization (BIO) and its Health Section Governing Board. He previously served as vice president and a member of the Board of Trustees of the Greater San Francisco Bay Area Leukemia & Lymphoma Society.